Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$11.60 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)456.10K
Market Cap
$193.48M
Enterprise Value-$6.17M
Total Cash (Recent Filing)$207.64M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 11, 2026EPS Estimate
-2.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.57
Shares Outstanding14,205,401
10 Day Avg. Volume467,908
30 Day Avg. Volume456,101
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.47
Enterprise Value/Gross Profit-0.95
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$41.33Price Target Upside174.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.43
Revenue Forecast (FY)$26.35M
Bulls Say, Bears Say
Bulls Say
Expanded TONMYA Payer CoverageBroad commercial and Medicaid formulary coverage materially improves long-term patient access and prescription opportunity for TONMYA. Durable reimbursement reduces a key barrier to uptake, supports sustained prescription volumes, and increases revenue visibility and negotiating leverage with providers and partners.
Positive Phase 3 Fibromyalgia EfficacyRobust Phase 3 efficacy and favorable benefit-risk metrics strengthen the product's regulatory and commercial prospects. Statistically significant, clinically meaningful results raise the odds of approval, payer support, prescriber adoption and potential licensing or partnership deals over the coming 2–6 months and beyond.
Stronger Balance Sheet With Low LeverageHigher equity and low debt provide financial flexibility to fund clinical programs and commercial launch activities without immediate solvency pressure. A larger capital base reduces near-term liquidity risk and supports strategic partnering or development investments while the company pursues approvals.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow depletes reserves and forces reliance on external financing. Over months this constrains R&D pacing, commercial investment and strategic optionality, increasing the probability of fundraising that can dilute existing shareholders or impose restrictive covenants.
Deep Operating Losses And Weak MarginsA structural mismatch between expenses and current revenue means the company must materially scale sales or cut costs to reach breakeven. Persistent large losses undermine return on capital and increase execution risk for clinical and commercial plans absent durable margin improvement or profitable products.
Reliance On External Funding And Dilution RiskAuthorization for reverse splits and new equity incentive tools signal management preparing for capital-structure actions. Combined with ongoing cash burn, this raises the likelihood of future equity raises or dilution, which can impair per-share economics and shareholder returns over the medium term.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $11.60 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $193.48M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 2 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported -$3.98 earnings per share for the quarter, missing the consensus estimate of -$3.19 by -$0.79.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.57.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 14,205,401 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$3.98 in its last earnings report, missing expectations of -$3.19. Following the earnings report the stock price went down -1.268%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (174.09% Upside)
$41.33 (174.09% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $286.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.01%
12-Months-Change
Fundamentals
Return on Equity
-60.15%
Trailing 12-Months
Asset Growth
70.16%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$41.33
▲(174.09% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
6.60% Mutual Funds
0.06% Other Institutional Investors
84.88% Public Companies and
Individual Investors